Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Livmarli study in Alagille syndrome and PFIC
NL-OMON60329Phase 4Recruiting
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of maralixibat in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) (3 cohorts), sponsored by Mirum Pharmaceuticals, Inc. Started Jan 2026; status: recruiting.
02
Drugs
maralixibat
03
Conditions
Alagille syndrome (ALGS)progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on NL-OMON60329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60329.